Barry Bonds TRT: The Private-Clinic Pathway They Likely Used

What the BALCO Investigation Revealed About Bonds' Alleged Protocol

The 2003 federal raid on the Bay Area Laboratory Co-Operative exposed a supply chain of testosterone, human growth hormone, EPO, and the then-undetectable designer steroid tetrahydrogestrinone (THG), nicknamed "the clear." Bonds was among the athletes whose names appeared in BALCO records. Grand jury testimony, later leaked and published, described a regimen that included a testosterone-based topical cream, injectable HGH, and insulin.

"The Cream" and "The Clear"

"The cream" was a compounded testosterone and epitestosterone blend applied topically. Its design was specific: by delivering both testosterone and its metabolite epitestosterone together, it kept the urinary testosterone-to-epitestosterone (T/E) ratio near 4:1, the threshold used by WADA-era drug testing. Epitestosterone itself has no androgenic effect; it was included purely to mask the exogenous testosterone.

THG, "the clear," was a synthetic anabolic steroid derived from gestrinone. It was genuinely undetectable until a track coach mailed a used syringe to the U.S. Anti-Doping Agency in June 2003. USADA then developed a test, and retrospective urine samples from multiple athletes came back positive. The FDA issued a warning about THG in October 2003, classifying it as an unapproved new drug and controlled substance. [1]

HGH and Insulin in the Stack

Grand jury testimony attributed to Bonds described injecting HGH, which promotes soft-tissue growth, lipolysis, and recovery, alongside insulin, which potentiates IGF-1 signaling and drives glucose and amino acids into muscle. This combination is well-documented in the sports-doping literature. A 2010 review in the Annals of Internal Medicine found that exogenous GH administration in athletes increased lean body mass by roughly 2 kg but produced no measurable improvement in strength or aerobic capacity, while significantly raising soft-tissue edema and the risk of diabetes. [2]

How the Private-Clinic Model Works, Then and Now

The "private clinic" is not inherently illegal. It describes a physician-run practice that evaluates, diagnoses, and treats hormonal conditions, often with a concierge or cash-pay model, outside the referral chain of a primary-care or academic endocrinology practice. BALCO's Victor Conte was not a physician; the physicians connected to BALCO operated at the fringe of this model, prescribing without appropriate diagnostic workup.

The Legitimate Diagnostic Pathway

A legitimate private TRT clinic follows the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men. [3] That guideline specifies:

• Two morning total testosterone measurements on separate days, both below 300 ng/dL, to confirm biochemical hypogonadism.
• Concurrent measurement of LH and FSH to distinguish primary from secondary hypogonadism.
• Symptom evaluation using a validated instrument such as the Androgen Deficiency in Aging Males (ADAM) questionnaire.
• Exclusion of contraindications: untreated prostate cancer, hematocrit above 54%, severe untreated sleep apnea, or desire for fertility in the near term.

The guideline states directly: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term." [3] Any clinic skipping this diagnostic cascade is operating outside the standard of care.

What a Legal TRT Prescription Actually Looks Like

Once hypogonadism is confirmed, the prescribing options are narrow and FDA-regulated. [4] Testosterone cypionate or enanthate injected intramuscularly at 100 to 200 mg every one to two weeks remains the most commonly prescribed formulation in private clinics because of its low cost and predictable pharmacokinetics. Subcutaneous injection at 50 to 100 mg weekly is increasingly used for steadier serum levels.

Topical gels, testosterone undecanoate capsules (Jatenzo, Tlando), and buccal systems (Striant) are alternatives. Pellet implants, popular in some concierge practices, deliver testosterone over 3 to 6 months but carry a higher risk of supraphysiologic peaks immediately post-implantation.

Monitoring follows a standardized schedule: total testosterone at 3 months post-initiation, targeting the mid-normal range (450 to 600 ng/dL), hematocrit every 3 to 6 months, PSA annually in men over 40, and lipid panel annually. [3]

Supraphysiologic Dosing Versus Replacement: The Clinical Difference

The gap between legitimate TRT and the BALCO-era protocol is the gap between replacement and supraphysiologic dosing. This distinction has measurable physiologic consequences that go well beyond sports ethics.

What Happens Above 1,000 ng/dL

A landmark dose-response trial by Bhasin et al. Published in the New England Journal of Medicine (N=61) demonstrated that graded testosterone doses from 25 mg to 600 mg weekly produced dose-dependent increases in fat-free mass and strength, but adverse effects, including erythrocytosis, HDL suppression, and testicular volume loss, also scaled with dose. [5] The 600 mg weekly group, still below what some athletes reportedly used, showed clinically significant hematocrit elevation and HDL depression compared to the 100 mg replacement-dose group.

Chronic supraphysiologic testosterone suppresses the hypothalamic-pituitary-gonadal axis completely. LH and FSH drop to near-zero, Sertoli cell function declines, and spermatogenesis may not recover for 12 to 24 months after cessation, and in some cases does not recover fully. [6]

HGH at Supraphysiologic Levels

The FDA has approved recombinant human growth hormone (somatropin) for adult growth hormone deficiency (GHD), short bowel syndrome, HIV-associated wasting, and a small number of other indications. [7] Prescribing it for athletic enhancement or anti-aging is off-label and, under the Anabolic Steroids Control Act and related statutes, distributing it for performance purposes is a federal felony.

At the doses reportedly used by BALCO clients (2 to 4 IU daily, vs. The 0.2 to 0.6 IU daily used in adult GHD replacement), GH causes acromegalic changes with prolonged use: jaw widening, hand and foot enlargement, carpal tunnel syndrome, and increased risk of colorectal neoplasia. A 2019 meta-analysis in The Lancet Diabetes and Endocrinology found that cancer incidence was elevated in patients with acromegaly compared to the general population, with standardized incidence ratios above 1.5 for colorectal cancer. [8]

The Legal and Regulatory Framework Around TRT Clinics

Testosterone is a Schedule III controlled substance under U.S. Federal law. HGH is regulated under a separate statute, the Safe Medical Devices Act amendment of 1990, which makes it a felony to distribute or possess GH for off-label performance use regardless of whether a prescription exists. [7]

DEA Oversight of Testosterone

The DEA requires that Schedule III prescriptions for testosterone be issued by a physician who has conducted a legitimate patient-physician relationship, including an in-person or telemedicine evaluation with documented diagnosis. Prescribing testosterone without a confirmed clinical indication is grounds for DEA license revocation and state medical board action.

State Medical Board Variation

State-level enforcement varies considerably. Florida and Texas have historically had higher concentrations of so-called "testosterone mills" that prescribe aggressively with minimal diagnostic workup. Several high-profile enforcement actions in Florida between 2010 and 2016 resulted in physician license revocations and federal indictments. A legitimate private TRT clinic distinguishes itself by documenting every diagnostic criterion before the first prescription is written.

What BALCO Actually Violated

Victor Conte was not a licensed physician. The physicians connected to BALCO who wrote prescriptions faced separate charges. Conte himself pleaded guilty in 2005 to one count of conspiracy to distribute steroids and one count of money laundering, serving four months in federal prison. The case established that distributing testosterone and HGH without a valid medical purpose, regardless of how prescriptions were obtained, constitutes a federal crime. [9]

Why Athletes in That Era Sought Private Clinics

Baseball had no formal drug-testing program for steroids until 2003, and HGH testing was not introduced until 2012 (blood testing under the Joint Drug Agreement). This regulatory vacuum meant that the only barrier between an athlete and a testosterone or HGH prescription was finding a willing physician.

The "Anti-Aging" Cover

Many BALCO-era prescriptions were routed through anti-aging medicine practitioners, a specialty that, at the time, lacked formal board certification standards. The American Academy of Anti-Aging Medicine (A4M) promoted GH and testosterone as tools to reverse physiologic aging, a claim not supported by randomized controlled trial data. A 2019 Cochrane review of GH supplementation in healthy older adults found no clinically meaningful improvement in physical performance or quality of life, with a signal toward increased adverse events. [10]

This framing gave athletes a plausible clinical rationale: they were patients receiving physician-supervised hormone optimization, not dopers taking illicit substances.

How Compounding Pharmacies Fit In

"The cream" from BALCO was compounded, not manufactured by an FDA-approved facility. Compounding pharmacies under Section 503A of the Food, Drug, and Cosmetic Act can prepare individualized formulations for specific patients based on a valid prescription. [11] They are not permitted to manufacture large batches for distribution without 503B outsourcing facility registration. BALCO's compound was produced and distributed without this framework entirely.

Legitimate compounding pharmacies today play a real role in TRT: they produce testosterone cypionate in concentrations not commercially available, prepare subcutaneous formulations, and compound testosterone cream for patients with gel allergies. The distinction between a licensed 503A pharmacy filling an individual prescription and an unlicensed facility producing bulk steroids for distribution is absolute.

What a Legitimate Private TRT Clinic Does Differently

A patient-centered private TRT clinic in 2025 operates under a framework that differs from the BALCO-era model on every meaningful dimension. The following criteria separate compliant clinics from problematic ones.

Diagnostic Rigor

Compliant clinics require two fasting morning serum total testosterone values below 300 ng/dL, drawn before 10 a.m. When diurnal variation peaks. They also measure free testosterone (calculated or equilibrium dialysis), SHBG, LH, FSH, prolactin, comprehensive metabolic panel, CBC, lipid panel, and PSA (men over 40). No prescription is written before this panel is complete and reviewed by the supervising physician.

Dose Targeting

Doses are calculated to bring total testosterone into the 450 to 600 ng/dL range, not to maximize it. Any patient presenting with values above 1,000 ng/dL at follow-up receives a dose reduction or injection-frequency adjustment before the next prescription is issued.

Monitoring Cadence

Follow-up labs are drawn at weeks 6 to 8 after initiation, then every 3 to 6 months. Hematocrit above 54% triggers a hold on testosterone pending phlebotomy or dose reduction, per Endocrine Society guidance. [3] PSA elevation above 1.4 ng/mL from baseline, or above 4.0 ng/mL absolute, triggers urology referral.

What a Compliant Clinic Will Not Prescribe

HGH for performance, anti-aging, or body composition in the absence of confirmed adult GHD (IGF-1 below the age- and sex-adjusted reference range, confirmed by stimulation testing) is not a service a compliant clinic offers. Insulin for non-diabetic patients is not prescribed. Designer or compounded steroids outside FDA-approved testosterone formulations are not on the formulary.

The Physiologic Markers That Flag Non-Replacement Use

Clinicians reviewing labs from a patient who has previously used supraphysiologic androgens will often see a recognizable pattern even years later.

Suppressed LH and FSH with low-normal testosterone suggests recent cessation of exogenous testosterone. Elevated hematocrit (above 50%) without a secondary cause, polycythemia vera excluded, raises the question of testosterone use. Testicular volume below 15 mL in a man with no history of cryptorchidism or orchitis may indicate prolonged HPG-axis suppression. [6]

A 2021 study in the Journal of Clinical Endocrinology and Metabolism (N=157) found that men with a history of anabolic steroid use had significantly lower LH, FSH, and total testosterone at two years post-cessation compared to age-matched controls, and 42% met biochemical criteria for hypogonadism, a finding that supports the case that some men develop genuine TRT-indication after prolonged steroid use. [12]

Should Bonds' Career Stats Be Contextualized Differently?

This is a journalistic question, not a clinical one, but the clinical data is relevant to it. The Bhasin dose-response data [5] shows that even at 600 mg weekly testosterone, the incremental strength gain over replacement dosing is real but not unlimited. HGH, per the Annals of Internal Medicine review, [2] adds lean mass without proportional strength gains.

Home run production in baseball depends on bat speed, contact mechanics, and reaction time, none of which are linear functions of testosterone or GH levels. The performance effect of the BALCO-era compounds was real at the level of recovery, body composition, and sustained training volume. It was not a switch that mechanically converted a good player into an all-time record holder.

That distinction belongs to sports historians. The clinical picture, though, is clear: chronic supraphysiologic androgen and GH exposure carries documented risks, no legitimate medical indication for healthy athletes, and measurable long-term consequences for the HPG axis.